Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module

SHANGHAI, China and SINGAPORE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biociences Co., Ltd ("Junshi Biosciences", HKEX: 1877, SSE: 688180), a leading innovation-driven biopharmaceutical company

Related Keywords

Guangzhou ,Guangdong ,China ,Zhui Feng ,Anhui ,Shanghai ,Singapore ,Suzhou ,Jiangsu ,Beijing ,Maryland ,United States ,San Francisco ,California ,Chinese ,Dotbio Pte ,Junshi Biosciences ,Zhi Li ,Eli Lilly ,Dotbio Dotbody ,Ignacio Asial ,Ltd Dotbio ,Shanghai Junshi Biociences Co Ltd Biosciences ,Ir Team ,Pr Team ,Chinese Academy ,Emergency Use Authorizations ,Junshi ,Iosciences ,Otbio ,Nnounce ,Collaboration ,Evelop ,Text ,Generation ,Ntibody ,Therapy ,Otbody ,Module ,